Mesothelioma Lung Cancer Phase 3 Study Vorinostat Report for Patients Like You

Filter by:

All
Start typing to see suggestions

patients

Home > Community Treatment Reports and Side Effects > Mesothelioma Lung Cancer Phase 3 Study Vorinostat Treatment Report

You appear to have JavaScript disabled in your browser. PatientsLikeMe relies on JavaScript and Cookies to deliver the best possible experience to you. How do I enable JavaScript?

What is Mesothelioma Lung Cancer Phase 3 Study Vorinostat?

NCT00128102 is a randomized, double-blind, placebo-controlled trial of oral suberoylanilide hydroxamic acid (Vorinostat, MK-0683) in patients with advanced malignant pleural mesothelioma previously treated with systemic chemotherapy. Other study name is MK-0683-014, 2005_010.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose	# of patients	# of patients with evaluations Efficacy	Major	Moderate	Slight	None	Can’t tell
Pleural Mesothelioma	1	0

See all 2 patients currently using Mesothelioma Lung Cancer Phase 3 Study Vorinostat

Mouse over the table for more information

Reported Schedules

	2 g every other week	36 other weekly
	1	1

Reported Duration See details about how long patients take this treatment ▼ Reported Duration Hide details ▲

Currently Using Mesothelioma Lung Cancer Phase 3 Study Vorinostat

A bar graph

0-1 month	1-3 months	3-6 months	6 months-1year	1-2 years	2 years or more
0	0	0	0	1	0

Report created on May 26, 2012.